Use of multimodality imaging, histology, and treatment feasibility to characterize a transgenic Rag2-null rat model of glioblastoma

• Published in: Frontiers in oncology Vol. 12; p. 939260
• Main Authors: Jackson, Luke R., Masi, Megan R., Selman, Bryce M., Sandusky, George E., Zarrinmayeh, Hamideh, Das, Sudip K., Maharjan, Surendra, Wang, Nian, Zheng, Qi-Huang, Pollok, Karen E., Snyder, Scott E., Sun, Phillip Zhe, Hutchins, Gary D., Butch, Elizabeth R., Veronesi, Michael C.
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 22.11.2022
• Subjects: amino acid PET; CEST MRI; glioblastoma; hybrid PET/MRI; magnetic resonance imaging (MRI); Oncology; positron emission tomography (PET); magnetic resonance imaging (MRI); glioblastoma; positron emission tomography (PET); hybrid PET/MRI; CEST MRI; amino acid PET; amide proton transfer (APT) imaging
• DOI: 10.3389/fonc.2022.939260
• ISSN: 2234-943X

Many drugs that show potential in animal models of glioblastoma (GBM) fail to translate to the clinic, contributing to a paucity of new therapeutic options. In addition, animal model development often includes histologic assessment, but multiparametric/multimodality imaging is rarely included despite increasing utilization in patient cancer management. This study developed an intracranial recurrent, drug-resistant, human-derived glioblastoma tumor in Sprague–Dawley Rag2 - Rag2 tm1Hera knockout rat and was characterized both histologically and using multiparametric/multimodality neuroimaging. Hybrid 18 F-fluoroethyltyrosine positron emission tomography and magnetic resonance imaging, including chemical exchange saturation transfer ( 18 F-FET PET/CEST MRI), was performed for full tumor viability determination and characterization. Histological analysis demonstrated human-like GBM features of the intracranially implanted tumor, with rapid tumor cell proliferation (Ki67 positivity: 30.5 ± 7.8%) and neovascular heterogeneity (von Willebrand factor VIII:1.8 to 5.0% positivity). Early serial MRI followed by simultaneous 18 F-FET PET/CEST MRI demonstrated consistent, predictable tumor growth, with exponential tumor growth most evident between days 35 and 49 post-implantation. In a second, larger cohort of rats, 18 F-FET PET/CEST MRI was performed in mature tumors (day 49 post-implantation) for biomarker determination, followed by evaluation of single and combination therapy as part of the model development and validation. The mean percentage of the injected dose per mL of 18 F-FET PET correlated with the mean %CEST (r = 0.67, P < 0.05), but there was also a qualitative difference in hot spot location within the tumor, indicating complementary information regarding the tumor cell demand for amino acids and tumor intracellular mobile phase protein levels. Finally, the use of this glioblastoma animal model for therapy assessment was validated by its increased overall survival after treatment with combination therapy (temozolomide and idasanutlin) (P < 0.001). Our findings hold promise for a more accurate tumor viability determination and novel therapy assessment in vivo in a recently developed, reproducible, intracranial, PDX GBM.